Compare MKC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKC | MDGL |
|---|---|---|
| Founded | 1889 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 12.8B |
| IPO Year | 2007 | 2005 |
| Metric | MKC | MDGL |
|---|---|---|
| Price | $55.19 | $542.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $67.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.6M | 366.6K |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 0.34 | N/A |
| EPS | ★ 4.33 | N/A |
| Revenue | ★ $6,840,300,000.00 | $180,133,000.00 |
| Revenue This Year | $16.24 | $58.39 |
| Revenue Next Year | $3.71 | $48.55 |
| P/E Ratio | $12.58 | ★ N/A |
| Revenue Growth | ★ 1.73 | N/A |
| 52 Week Low | $44.82 | $393.61 |
| 52 Week High | $72.41 | $615.00 |
| Indicator | MKC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 46.08 |
| Support Level | $49.91 | $497.85 |
| Resistance Level | $54.41 | $545.13 |
| Average True Range (ATR) | 1.28 | 17.19 |
| MACD | 0.00 | -0.69 |
| Stochastic Oscillator | 47.03 | 29.60 |
In its 135-plus-year history, McCormick has become the leading global manufacturer of spices, herbs, extracts, seasonings, and other flavorings. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula. This mix will be complemented by the pending addition of Unilever's food brands, primarily Knorr cooking aids and Hellmann's mayonnaise. After the deal close, the combined business is slated to generate 70% of sales from consumers and 30% from restaurants and other packaged food and beverage manufacturers. Around 40% of sales are slated to come from faster-growing emerging markets, with Europe (23%) and North America (36%) accounting for the remainder.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.